Biomarker assays could increase the accuracy of noninvasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estimated to miss 27%-47% of CRCs and 70%-80% of advanced adenomas per round of screening. We investigated the conditions under which biomarker screens would be cost-effective compared with FIT screens of average-risk individuals.
an earlier stage when treatment is potentially more effective. Guaiac fecal occult blood tests (gFOBTs) and fecal immunochemical tests (FITs) detect traces of blood in stool and are widely used for noninvasive screening. 2 However, even the newer versions have a limited sensitivity, especially for adenomas. It is estimated that FIT misses 27%-47% of CRCs and 70%-80% of advanced adenomas per screening round. 3, 4 Improved performance of noninvasive screening could be obtained by testing for disease-specific molecules such as DNA in stool or blood, when added to or replacing FIT. 5 Molecular biomarkers have been investigated extensively, and ongoing technical innovations have improved the feasibility to use such tests for mass screening. Exact Sciences Corp (Madison, WI) has developed a multi-target stool DNA test, which consists of multiple DNA mutation and methylation markers and also includes a measure of hemoglobin. Recently data were published from the first screening trial. 6 Although the sensitivity for CRC of this particular test is higher than FIT, to be considered for implementation in population-based screening programs, any new test should be both effective and cost-effective compared with current screening options.
Research and analysis methods in biomarkers for CRC are still developing, and test performance and costs are not yet settled. Therefore, the aim of this study was to provide insight in the requirements for test sensitivity, specificity, and unit cost for new technologies to be costeffective compared with FIT screening in populationbased screening programs.
Materials and Methods
We used the MISCAN-Colon microsimulation model to estimate life-years gained (LYG) and costs of various screening scenarios. We modeled a range of hypothetical biomarker tests with varying specificity and sensitivity for adenomas and CRC and compared the outcomes with those of optimal FIT screening. For each biomarker test variant we varied the screening age range and interval and calculated the threshold unit cost allowed to be cost-effective compared with FIT screening.
MISCAN-Colon Microsimulation Model
The MISCAN-Colon model and the data sources that informed the quantifications of the model are described in detail in Supplementary Appendix 1 and in previous publications. [7] [8] [9] [10] [11] In brief, the MISCAN-Colon model simulates the life histories of individuals from birth to death. CRC arises in the population according to the adenomacarcinoma sequence. 12, 13 More than 1 adenoma can occur in an individual, and each adenoma can independently develop into CRC. Adenomas can progress in size from small ( 5 mm) to medium (6-9 mm) to large (!10 mm), and some may eventually become malignant. A preclinical (ie, not detected) cancer has a chance of progressing through stages I to IV and may be detected by symptoms at any stage. After clinical diagnosis of CRC, survival depends on the stage at diagnosis. At any time during his/her life an individual may die of other causes.
With stool-based or blood-based screening, an individual with a positive test will be referred for diagnostic colonoscopy for possible removal of adenomas and detection of cancers. In this way CRC mortality can be reduced. The LYG by screening are calculated as the difference in model-predicted life-years lived in the population with and without CRC screening.
Study Population
We modeled a cohort of individuals at average risk of CRC. The age-specific all-cause mortality was based on the 2010 Dutch life tables. The simulated CRC incidence rate and CRC stage distribution were calibrated to observed data in The Netherlands from 1999 to 2003, which was before the onset of opportunistic screening.
14 Survival rates after clinical diagnosis of CRC before age 75 were based on CRC relative survival data from 1985 to 2004. 15 The survival for individuals diagnosed at age 75 and older was based on the under 75 survival rates and adjusted to fit the observed age-increasing mortality/incidence ratio.
Test Characteristics
The test characteristics of FIT (Table 1) were fitted to the positivity and detection rates of adenomas and CRC observed in the first screening round of 2 Dutch randomized trials using OC-Sensor (Eiken, Japan). [16] [17] [18] We modeled FIT with a cutoff level of 10 mg/g feces (50 ng/mL buffer) because this was previously found to be the most cost-effective. 19 We considered various biomarker test variants with sensitivities for CRC ranging from 60% to 100% at 10% increments ( Table 1 ). The sensitivity for adenomas varied, by assumption, by the same proportions as the sensitivity for CRC. For example, when increasing the sensitivity for CRC from 70% to 80%, the sensitivity for adenomas was also increased by a factor of 1.14 (80/70). For the biomarker test variants, the specificity was varied from 88% to 100% at 2% increments. Varying both sensitivity and specificity resulted in 35 (5 Â 7) different sets of test characteristics.
The sensitivity of diagnostic and surveillance colonoscopies was assumed to be 75% for adenomas 5 mm, 85% for adenomas 6-9 mm, and 95% for adenomas !10 mm and CRC. 20 We assumed costs for biopsy and pathology in 10% of the population without adenomas detected for detection and removal of hyperplastic or other polyps that are not explicitly simulated in the model. 21 
Screening Scenarios
We considered different screening schedules by varying age to start screening (45, 50, 55, or 60 years), age to stop screening (70, 75, or 80 years), and screening interval (1, 1.5, 2, 3, 5, 7, or 10 years). These screening age ranges and intervals resulted in 84 (4 Â 3 Â 7) different screening schedules, and combining them with the different biomarker test variants resulted in approximately 3000 unique screening scenarios. We compared the outcomes of these strategies with the outcomes of optimal FIT screening strategies as identified in a previous analysis. 22 In the base-case analysis, we simulated individuals who follow the screening, follow-up, and surveillance recommendations, assuming participation and compliance would be equal between the tests. Individuals with a positive test result would be referred for diagnostic colonoscopy. If no adenomas were found during the procedure, the individual, as recommended, would return to the regular screening program after 10 years. If 1 or more adenomas were found, they would be removed, and the individual would enter surveillance according to the Dutch guidelines for follow-up after polypectomy that were used until recently, 23 which indicates colonoscopy after 6 years in case of 1 or 2 adenomas and after 3 years in case of 3 or more adenomas.
Costs
An overview of cost inputs used in the model is presented in Table 2 . The analysis was conducted from a modified societal perspective. This means that next to direct medical costs, patient time costs were also included. 27 Costs for FIT screening, complications after colonoscopy, and treatment of CRC have been published previously. 19 By using the medical cost price index from the Dutch Health Care Authority, we updated those costs to the year 2013. 28 In addition, the costs for colonoscopy procedures were based on a recent internal study at the Dutch Erasmus Medical Centre (unpublished data) in the setting of a dedicated screening center. We assumed that the biomarker tests would have organizational costs (ie, costs for the mailing of invitations, reminders, and test results, gathering of address information of eligible participants, and overhead of the screening organization) equal to those of FIT screening. No assumptions for costs were made for the hypothetical biomarker test, because these costs were subject of the analysis.
Cost-effectiveness and Threshold Costs
We estimated costs and LYG of each scenario compared with no screening, discounted by 3% per year. 29 Subsequently, on the basis of these results, we also compared different scenarios to each other. Scenarios that were more costly and less effective than other scenarios (simple dominance) or than a mix of other scenarios (extended dominance) were ruled out. The remaining scenarios are not dominated and are known as "efficient". On a plot of costs versus LYG, the line that connects the efficient scenarios is called the efficient frontier, which implies that all dominated scenarios lie below this line. The incremental costeffectiveness ratio (ICER) of an efficient scenario was determined by comparing its additional costs and effects with those of the next less costly and less effective efficient scenario. Probability of a person to test positive (person-level sensitivity) is higher than per-lesion sensitivity and depends on number and type of lesions present as well as probability to test positive because of other reasons such as bleeding from a diverticulum. b It was assumed that the probability a CRC bleeds and thus the sensitivity of FIT for CRC depends on time until clinical diagnosis, in concordance with findings for gFOBT, which were based on prior calibration of MISCAN-Colon model to 3 gFOBT trials. 9 This result is to be expected when cancers that bleed do so increasingly over time, starting occultly and ending as clinically visible. c Test characteristics of FIT (at cutoff of 10 mg/g feces [50 ng/mL buffer]) were fitted to positivity and detection rates of adenomas and CRC from 2 Dutch randomized trials. [16] [17] [18] We assumed that the sensitivity for small adenomas was 0%, and that small adenomas would only be detected because of lack of specificity of the test. d We modeled 5 different sets of sensitivities for the biomarker test. All 5 sets of sensitivities were modeled with specificities ranging from 88% to 100% at 2% increments, yielding a total of 35 (5 Â 7) different sets of test characteristics for the hypothetical biomarker tests variants. e Colonoscopy was only used during follow-up and surveillance after positive FIT or biomarker test.
In the analysis of threshold unit costs, for each biomarker test variant an efficient frontier was determined from the various screening age ranges and intervals considered. Subsequently, for each scenario on the efficient frontier we calculated the cost per biomarker test that is allowed for that scenario to be on the efficient frontier of FIT. The resulting cost level may vary over the screening intensities, and we considered the highest value as the threshold unit cost for each biomarker test variant. For biomarker scenarios that were more effective than the most effective FIT scenario, the threshold cost for the biomarker scenario was calculated on the basis of a maximal willingness-to-pay of V50,000 ($56,000) per additional LYG relative to the most effective FIT scenario.
Outcomes
The main outcomes are costs and LYG per 1000 individuals compared with no screening for various unit costs of the new test and threshold unit cost required for equal cost-effectiveness compared with FIT.
Sensitivity Analyses
We considered several sensitivity analyses, summarized in Supplementary [16] [17] [18] and screening uptake using the biomarker test variants would be either 20% point higher or lower than FIT. Fourth, we assumed an ICER of V100,000 ($112,000) per LYG as the upper limit for any scenario to be considered cost-effective. Fifth, we used the test characteristics for FIT (at a cutoff of 20 mg/g feces [100 ng/mL buffer]) as published by Imperiale et al 6 in their direct comparison of FIT with the multitarget stool DNA test. Sixth, we alternatively increased and decreased the costs of colonoscopy and CRC treatment. Finally, we replaced all CRC screening and treatment costs from The Netherlands with U.S. costs. For this analysis we used cost estimates as published by Zauber et al, 30 and we adjusted them to 2013 U.S. dollars by using the U.S. Consumer Price Index for all items (Supplementary Table 4) . 31 Because of the opportunistic nature of screening in the United States, we did not consider organizational costs in this setting.
Results
The optimal FIT screening strategies varied in LYG from 38.4 per 1000 screening participants with 2 For calculation of patient time costs we assumed an average hourly wage of V15.93. 24 We assumed 1, 16, and 112 hours of patient time per procedure for FIT and biomarker testing, colonoscopy (including bowel preparation), and colonoscopy complications, respectively. For CRC treatment we assumed 244, 19, and 283 hours of patient time per year of care in initial treatment, continuous care, and terminal care, respectively.
25,26
b Organizational costs for screening were based on the Dutch cervical cancer screening program, adjusted for differences with FIT screening, and include costs for administration, education, and quality assurance. c Includes V2.48 for test kit and V4.81 for analysis. d Unit cost of biomarker test variants (test kit and analysis of the test) was determined in the threshold analysis. e For non-attenders (sensitivity analysis) the test analyses and patient cost were not applied. f Cost per complication. We assumed a complication rate of 2.4 per 1000 colonoscopies. g CRC treatments were divided into 3 clinically relevant phases: initial, continuous, and terminal care. Initial phase was defined as first 12 months after diagnosis, terminal phase was defined as final 12 months of life, and continuous phase was defined as all months between the initial and terminal phases. For patients surviving less than 24 months, the final 12 months were allocated to the terminal phase. The remaining months of observation were allocated to the initial phase.
screens at age 60 and 72 to 118.8 with annual screening between age 45 and 80 ( Figure 1 ). The costs varied from V16,600 to V611,700 ($18,600-$686,000), respectively. LYG with a biomarker test with 90% sensitivity for CRC, 48% for advanced adenomas, and 88% specificity were higher than with FIT and varied between 47.0 and 121.0. For example, for biennial screening between ages 55 and 75 years (the schedule currently used in the Dutch program), the LYG were 84.9 with FIT, compared with 95.8 with the considered biomarker test. At unit costs of V50 ($56) per test, the biomarker test was dominated by FIT screening ( Figure 1A ). Most biomarker strategies saved fewer LYG than FIT for the same costs or required more costs to save the same number of LYG. Only a handful of biomarker strategies were more effective than the most effective FIT strategy (eg, annual screening from age 45 to 80). However, with unit costs of V50 ($56), the additional costs of these tests were so much greater that they were not in balance with the additional benefits (ie, exceeded V50,000 [$56,000] per LYG).
At unit costs of V15 ($17) per test ( Figure 1B ), several of the biomarker strategies resulted in more LYG than FIT screening for the same level of costs or lower costs for the same level of LYG. At unit costs of V25 ($28) per test ( Figure 1C ), there was 1 biomarker strategy on the efficient frontier of FIT screening, indicating that this strategy was cost-effective compared with FIT. All other strategies with the same biomarker test were dominated by FIT screening, indicating that V25 ($28) per test is the maximum cost for which this particular biomarker strategy (ie, 90% sensitivity for CRC, 48% sensitivity for advanced adenomas, and 88% specificity) could be cost-effective in comparison with FIT screening.
Threshold Costs for Biomarker Tests
Considering the range of hypothetical biomarker test variants, the threshold costs varied considerably (Table 3 ). The threshold costs increased with test performance up to V50.23 ($56.34) (approximately 7 times the unit cost of FIT) at the highest performance level considered. On the other hand, thresholds below the V7 ($8) for FIT were possible in instances where test Figure 1 . Net costs and LYG (3% discounted) of efficient FIT screening strategies and of screening strategies with a hypothetical biomarker with 90% sensitivity for cancer, 48% for advanced adenomas, and 88% specificity. Biomarker tests costs are equal to V50 ($56) in (A), to V15 ($17) in (B), and V25 ($28) in (C). Each symbol represents a strategy that differs with respect to age to begin screening, age to end screening, and screening interval. specificity would be sacrificed to get improved sensitivity, resulting in increased numbers of colonoscopy.
Sensitivity Analyses of Threshold Costs
The maximal colonoscopy demand in the base-case analysis was approximately 55 per 1000 individuals (annual screening with a low specificity test). When the analysis was limited to scenarios with a colonoscopy demand not exceeding 10 colonoscopies per 1000 individuals per year, the test variants with 88%-92% specificity were not cost-effective compared with FIT (with 94% specificity) at any unit cost. In contrast, with higher specificity levels the threshold costs strongly increased up to V214-V437 ($240-$490) for perfect specificity (V11-V50 [$12-$56] in the base-case analysis).
Regarding differences in screening uptake, a 20% point greater screening uptake with biomarker screening increased maximum threshold costs from V50 ($56) to V238 ($267), whereas a 20% point lower screening uptake decreased maximum threshold cost to V18 ($20). Assuming U.S. cost levels, which are approximately 25% higher for screening and more than double for treatment, this approximately doubled the maximum threshold costs to $105 ($118).
The estimated threshold costs for the biomarker test variants were robust to most alternative assumptions considered, with threshold costs not exceeding V100 ($112) (Supplementary Table 5 ).
Discussion
This study demonstrates that when taking FIT as a reference, the threshold unit cost of the biomarker test variants allowed for equal cost-effectiveness compared with a sensitive FIT was V50 ($56) for a test with the highest considered performance characteristics (53% and 100% sensitivity for large adenomas and CRC, respectively, and 100% specificity). The results were sensitive to differences in screening uptake between FIT and the biomarker tests (maximum V238 [$267] at 20% higher uptake) and cost assumptions (threshold costs of $105 [$118] for U.S. cost assumptions). Also, in a situation with limited colonoscopy capacity, improving specificity would become more important, so that with a 20% capacity level (compared with the level needed for annual screening with FIT), the maximum threshold costs would become V437 ($490) for a high-specificity test. Together these results point to key determinants that need to be addressed to improve (incremental) cost-effectiveness of biomarker testing: cost, sensitivity for advanced (progressive) adenomas, specificity, and compliance.
Improving the sensitivity and specificity did not greatly increase the threshold cost compared with FIT mainly because CRC is a slow growing disease, and the time for progressive adenomas to develop and progress into cancer takes on average more than 10 years, 12, 13 although there will be a variation in duration, especially for certain cancer types. Although FIT has limited test sensitivity, it can be performed multiple times at relatively low costs, resulting in considerably higher program sensitivity. When FIT at short intervals is excluded from the comparison because colonoscopy capacity is insufficient for such high-intensity screening, FIT screening becomes considerably less effective. This in turn has a strong positive impact on the threshold costs of biomarker tests with high specificity. Because these tests require fewer colonoscopies, they can be offered at greater frequency than the FIT test. Especially when they are also more sensitive, this will result in significantly more LYG from screening than with the less intensive FIT strategies. In such a situation higher costs are warranted and under perfect sensitivity and specificity unit costs of up to V437 ($490) would still be cost-effective.
The lower sensitivity of FIT for adenomas than for CRC provides more room for improving adenoma rather than CRC detection. In fact, one could argue that it would make more sense to detect and intervene with lesions before they have become malignant, similar to cervical cancer screening. In addition, the preclinical duration of adenomas is longer than that of CRC, and earlier detection of CRC has a smaller impact on treatment costs than preventing CRC through the removal of adenomas. On the other hand, improving adenoma sensitivity beyond the 53% we considered for large adenomas without losing too much on specificity would also be challenging. The threshold costs of biomarker tests could also further increase if the test would be able to discriminate between progressive and non-progressive adenomas. 32 With such a test, fewer unnecessary colonoscopies and polypectomies would be performed for people with nonprogressive adenoma, reducing the burden and resources for screening while maintaining the same benefit. For a stool-based biomarker test a considerable difference in screening uptake seems unlikely because the method of sample collection and therefore the barriers may be very similar to FIT. A blood-based biomarker provides a different test modality, which could potentially be more acceptable for individuals who currently choose not to participate in stool-based screening. However, current blood-based biomarker tests have fairly low sensitivity. 33, 34 On the other hand, people could be attracted by the novelty of a DNA-based testing methodology and the higher expected performance characteristics of new stool-based biomarkers compared with FIT. In addition, these new tests may be offered with patient navigation, as is the case for the multi-target stool DNA test, which may increase test uptake and thus comparative cost-effectiveness of the test. However, uptake increases of more than 20% are unlikely, because FIT can also be offered with patient navigation.
Several studies have evaluated the cost-effectiveness of specific biomarker tests. [35] [36] [37] [38] [39] [40] [41] [42] The majority of the studies considered various versions of the fecal DNA test, and unit costs, including laboratory analysis, varied between $51 (Taiwanese population) and $825 (U.S. population). One study evaluated a blood-based methylated Septin 9 DNA assay at a cost of $150 per test. 36 In general, DNA testing was found to be cost-effective compared with no screening but was not cost-effective compared with other screening options, including Hemoccult II, FIT, and colonoscopy. This is consistent with our findings. One study showed that the multitarget stool DNA test could be cost-effective at its current reimbursement rate of $493 if the test yielded participation rates more than 1.7-fold relative to FIT. 37 This finding closely aligns with our estimate that threshold costs could be V238 ($267) at 20%-point higher participation rates (1.3-fold relative to FIT).
Two publications investigating the Exact Sciences test (version 1.1; Madison, WI) reported threshold costs of $34-$60, compared with FIT. 39, 40 In our analysis, the threshold costs for corresponding sensitivity and specificity values are somewhat lower, which may be explained by us using the more cost-effective cutoff of 10 instead of 20 mg/g feces (50 instead of 100 ng/mL buffer) for FIT (resulting in higher sensitivity and lower specificity for FIT), and to the Dutch costs assumptions compared with the U.S. setting.
Our study adds to previous publications by providing threshold costs for newer test versions. For example, for the multi-target stool DNA test, 6 with a sensitivity for CRC of approximately 90% and a specificity of 90%, the threshold unit costs would need to be less than $56 compared with FIT in the U.S. setting (Supplementary Appendix 2). This broader range of results is important because analysis methods, using DNA as well as other reporter molecules including proteins and microRNA, are still developing, and test performance and costs are not yet settled. Moreover, our study provides researchers and manufacturers with data to determine the requirements of their test to be cost-effective compared with current alternatives.
This study has 4 potential limitations to be mentioned. First, we did not explicitly model distinct pathways for traditional and sessile serrated adenomas/ polyps (SSA/P). The average time it takes for an adenoma to develop into CRC was calibrated to the randomized United Kingdom flexible sigmoidoscopy screening trial 43 and included both traditional and SSA/P. Therefore, both adenoma types are included in the modeled mix of slow and rapid progressing lesions. Using the data from a flexible sigmoidoscopy study to estimate the progression time off SSA/P to CRC may not be most reflective because of the tendency of more significant SSA/P to be right-sided and proximal CRC precursors. We would underestimate the relative effectiveness of biomarkers compared with FIT only if SSA/P would have higher malignant potential than conventional adenomas, and the biomarker sensitivity for SSA/P would be greater than FIT sensitivity. Evidence is accumulating that FIT might be less sensitive for SSA/P, possibly because of an absence of or limited number of surface vessels or because they are often flat and therefore less likely to bleed. 6, [44] [45] [46] However, evidence for the malignant potential of SSA/P remains to be determined.
Second, we assumed independency of test results between screening rounds for both FIT and biomarker tests. However, systematic false-negative results could negatively impact the effectiveness of screening. There is evidence indicating systematic false-negative test results with FIT screening, presumably because of non-bleeding lesions. 47, 48 It is unlikely that our assumption of independency of test results has influenced our results substantially. Previous analyses showed that systematic test results reduced LYG by screening by approximately 5%. 47 Because of the genetic heterogeneity in carcinogenesis and the limited number of DNA markers analyzed in DNA tests, systematic negative test results are likely to affect biomarker screening as well. Because of the modest impact of systematic test results on effectiveness and the expectation that biomarker tests will be affected similarly, we expect the bias in our comparison of both tests to be limited. Combining hemoglobin markers with DNA markers in one test as with the multi-target stool DNA test may be a tool to address the concern of subsequent systematic negative test results. However, results of multiple rounds of testing with multi-target stool DNA are needed to confirm this hypothesis.
Third, we based our stage-specific CRC survival estimates on data from the south of the Netherlands (period 1985-2004), whereas recently data became available with national coverage and from a more recent time period (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . Compared with the current model, the 5-year relative survival has increased less than 4%. In a sensitivity analysis, we estimated that even a 25% increase in the relative survival for all stages would not change the calculated threshold unit costs by more than V2 ($2.25).
Finally and maybe most importantly, we only considered sensitivities of the new biomarker tests for advanced adenomas of up to 53% because of our assumption that the sensitivity for advanced adenoma increases with the same rate as the sensitivity for CRC. However, sensitivity of the current multi-target stool DNA test for advanced adenomas already exceeds 40%, approaching 70% for adenomas with high-grade dysplasia. 6 Also, because only about 5% of adenomas progress to cancer 49 and specific patterns of molecular alterations are associated to this progression, 50 there is a rationale for an alternative approach where only a subset of (advanced) adenoma, ie, high-risk adenomas, and early stage curable cancers are the screening target. 32 In such a scenario, a test with a sensitivity of 53% for advanced adenomas might have a higher sensitivity for the actual high-risk adenomas. It is therefore not unlikely that further improvements of biomarker tests may lead to sensitivities for advanced adenoma exceeding 53%. In that case, the number of screening rounds with the biomarker test may be reduced, which would positively impact threshold costs or the test. Improvement of adenoma sensitivity could therefore be an important area of future innovation. However, it is very important that this innovation would not come at the expense of a too great loss in specificity, because our results clearly indicate how sensitive threshold costs of new biomarker tests are to its specificity.
In conclusion, in case of greatly improved overall performance, the unit cost of a biomarker test should not exceed approximately 7 times the unit cost of FIT for cost-effectiveness. This maximum would increase substantially if colonoscopy gets more expensive or scarce, or if the new test has higher screening uptake. Our findings provide a framework for researchers to estimate the potential added value of new biomarkers compared with current FIT screening. 
Supplementary Material

Supplementary Appendix 1. Description of the MISCAN-Colon Model
Model Overview
The MISCAN-Colon model is a semi-Markov microsimulation model. The population is simulated individual by individual, and each person can evolve through discrete disease states. However, instead of modelling yearly transitions with associated transition probabilities, the MISCAN-Colon model generates durations in states. This improves model performance. With the assumption of exponential distribution of the duration in each state, this way of simulating leads to the same results as a Markov model with yearly transition probabilities. The advantage of the MISCAN approach is that durations in a certain state need not necessarily be a discrete value but can be continuous. MISCAN uses the Monte Carlo method to simulate all events in the program. Possible events are birth and death of a person, adenoma incidence, and transitions from one state of disease to another.
The basic structure of MISCAN-Colon is illustrated in Supplementary Figure 1 . This figure clearly demonstrates that MISCAN-Colon consists of 3 parts: demography part natural history part screening part.
These parts are not physically separated in the program, but it is useful to consider them separately.
Demography Part
The demography part of the model simulates individual life histories without CRC to form a population. For each person, a date of birth and a date of death of other causes than CRC are simulated. The distribution of births and deaths can be adjusted to represent the population simulated. For example, a population of white women will have higher death ages than a population of black men.
Natural History Part
The natural history part of MISCAN-Colon simulates the development of CRC in the population. We assume all CRCs cancers develop according to the adenomacarcinoma sequence of Figure 2) . A personal risk index is generated for each individual in the simulated population. Subsequently, adenomas are generated in the population according to this personal risk index and an age-specific incidence rate of adenomas. This results in no adenomas for most persons and 1 or more adenomas for others. The distribution of adenomas over the colorectum is simulated according to the observed distribution of CRC incidence. Each of the adenomas can independently develop into CRC. Adenomas can progress in size from small (1-5 mm) to medium (6-9 mm) to large (10þ mm). Most adenomas will never develop into cancer (non-progressive adenomas), but some (progressive adenomas) may eventually become malignant, transforming to a stage I cancer. The cancer may then progress from stage I to stage IV. In every stage there is a chance of the cancer being diagnosed because of symptoms. The survival after clinical diagnosis depends on the stage of the cancer.
Screening Part
Screening interrupts the development of CRC. With screening, adenomas may be detected and removed, and cancers may be found, usually in an earlier stage than with clinical diagnosis. In this way, screening prevents CRC incidence or CRC death. The LYG by screening are calculated by comparing the modelpredicted life-years lived in the population with and without screening. The effects of different screening policies can be compared by applying them to identical natural histories.
Integration of the Three Model Components
For each individual, the demography part of the model simulates a time of birth and a time of death of other causes than CRC, creating a life history without CRC (top line in Supplementary Figure 3) . Subsequently, adenomas are simulated for that individual. For most individuals no adenomas are generated for other multiple. In the example in Supplementary Figure 3 , the person gets 2 adenomas (second and third lines). The first adenoma arises at a certain age, grows into 6-9 mm, and eventually becomes larger than 10 mm. However, this adenoma does not become cancer before the death of the person. The second adenoma is a progressive adenoma. After having grown to 6-9 mm, the adenoma transforms into a malignant carcinoma, causing symptoms and diagnosis and eventually resulting in an earlier death from CRC. The life history without CRC and the development of the 2 adenomas in Supplementary Figure 3 together lead to the combined life history, with CRC depicted in the bottom line. Because this person dies of CRC before he dies of other causes, his death age is adjusted accordingly.
After the life history of a person is adjusted for CRC, the history will now be adjusted for the effects of screening. The effect of screening on life history is explained in Supplementary Figure 4 .The top line in this figure is the combined life history for CRC from Supplementary Figure 3 . The development of the separate adenomas is repeated in the second and third lines. In this picture there is 1 screening intervention. During the screening both prevalent adenomas are detected and removed. This results in a combined life history for CRC and screening (bottom line). From the moment of screening the adenomas are removed, and this individual becomes adenoma and carcinoma free. He does not develop cancer because the precursor lesion has been removed. Therefore, the person dies at the moment of death of other causes, and the effect of screening is the difference in life-years in the situation without screening and the situation with screening. Of course, many other possibilities could have occurred; a person could have developed new adenomas after the screening moment, or an adenoma could have been missed by the screening test, but in this case this individual really benefitted from the screening intervention.
Model Quantification
Demography Parameters
In all runs a cohort of individuals was modelled with age-specific all-cause mortality that was based on the 2010 Dutch life tables.
Natural History Parameters
The parameters for natural history model that could not be directly estimated from data or fit to reference data were established on the basis of expert opinion. At 2 expert meetings at the National Cancer Institute on June 5-7, 1996, and May 12-13, 1997, a model structure was devised in agreement with the currently accepted model of the adenoma-carcinoma sequence. It was assumed that all cancers are preceded by adenomas.
The average duration between onset of a progressive adenoma and the transition to preclinical cancer was calibrated to data from the United Kingdom flexible sigmoidoscopy screening trial. 3 The duration of cancer in preclinical stages was estimated on the basis of the results of 3 large randomized controlled screening trials. 3 This resulted in an average duration of 2.5 years, 2.5 years, 3.7 years, and 1.5 years for stages I-IV, respectively, with a total average duration of 6.7 years because not every cancer reaches stage IV before clinical diagnosis. All durations were governed by an exponential probability distribution. Durations in each of the invasive cancer stages as well as durations in the stages of the noninvasive adenomas were assumed to be 100% associated with each other, but the durations in invasive stages as a whole were independent of durations in noninvasive adenoma stages that precede cancer. These assumptions resulted in an exponential distribution of the total duration of progressive noninvasive adenomas and of the total duration of preclinical cancer, which has also been used in other cancer screening models. 4, 5 It was assumed that 30% of the cancers arise from adenomas of 6-9 mm and that 70% arise from larger adenomas. Initially, the preclinical incidence of progressive adenomas was chosen to reproduce the CRC incidence by age, stage, and localization in the Netherlands in 1999-2003, which was before the onset of opportunistic screening. 6 The size distribution of adenomas over all ages was assumed to be 73% for stages less than or equal to 5 mm, 15% for stages 6-9 mm, and 12% for stages greater than or equal to 10 mm. 7 The preclinical incidence of non-progressive adenomas that will never grow into cancer was varied until the simulated prevalence of all adenomas was in agreement with data from autopsy studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The anatomic site distribution of both progressive and non-progressive adenomas and thus of preclinical and clinical cancers is assumed to be equal to the site distribution of CRCs in the Netherlands in 1999-2003. 6 The stage-specific survival after the clinical diagnosis of CRC before age 75 is taken from the Comprehensive Cancer Centre South from 1989-2003. 18 The survival for individuals aged 75 years and older was adjusted to fit the observed age-increasing mortality/incidence ratio. Supplementary Table 1 contains a summary of the model input values and its data sources.
Screen Parameters
We assumed a cecal intubation rate of 95%. [19] [20] [21] The sensitivity of colonoscopy for each lesion within realized reach was based on back-to-back colonoscopy studies: 75% in adenomas less than or equal to 5 mm, 85% in adenomas 6-9 mm, and 95% in adenomas greater than or equal to 10 mm and cancers (Supplementary Table 2) . 22 After a positive test, all lesions are removed within a short time. The percentage of the population without adenomas or cancer but with hyperplastic polyps, lipomas, or other lesions that lead to polypectomy and pathology after colonoscopy has been estimated from Kaiser data 23 as 10%. This percentage was assumed to be independent of the screening round.
The stage-specific survival of patients with screendetected cancer was based on a previous analysis calibrating on 3 large randomized FOBT trials 3 and was more favorable than survival after diagnosis in the same stage without screen detecting. Removal of an adenoma always prevents development of any subsequent cancer that may have arisen from this adenoma. Risks of complications reported in organized screening programs [24] [25] [26] are lower than those reported for general practice colonoscopies. 27, 28 The major complications of colonoscopy are perforations (which can occur with or without polypectomy), serosal burns, bleeds requiring transfusion, and bleeds not requiring transfusion. [24] [25] [26] [27] [28] We estimated a rate of death of 1 per 30,000 for colonoscopies with a polypectomy. Fit to multiplicity distribution of adenomas in autopsy studies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Adenoma incidence in general population Test characteristics of FIT Estimated from 2 Dutch randomized screening trials by using cutoff level of 50 ng hemoglobin/mL [33] [34] [35] As published in the study from Imperiale et al, 36 using cutoff level of 100 ng hemoglobin/mL Colonoscopy costs, including complications See For calculation of patient time costs we assumed an average hourly wage of $22.01. 37 We assumed 1, 16, and 112 hours of patient time per procedure for FIT and biomarker testing, colonoscopy (including bowel preparation), and colonoscopy complications, respectively. For CRC treatment we assumed 244, 19, and 283 hours of patient time per year of care in initial treatment, continuous care, and terminal care respectively.
Input
38,39
b Because most screening in the U.S. is performed opportunistically, we assumed no organizational costs. Cost of the FIT test kit and analysis is based on Medicare reimbursement rate. c Costs for patient navigation were not included. d We assumed a complication rate of 2.4 per 1000 colonoscopies. e CRC treatments were divided into 3 clinically relevant phases: initial, continuous, and terminal care. Initial phase was defined as first 12 months after diagnosis, terminal phase was defined as final 12 months of life, and continuous phase was defined as all months between initial and terminal phases. For patients surviving less than 24 months, the final 12 months were allocated to the terminal phase. Remaining months of observation were allocated to the initial phase. 60 5 
